Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8754)
All Articles published online
|
Nov 14, 2012 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol 2012; 18(42): 6005-6017 [PMID: 23155330 DOI: 10.3748/wjg.v18.i42.6005] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v18/i42/6005.htm |
| Number | Citing Articles |
| 1 |
Takahiro Yamasaki, Issei Saeki, Isao Sakaida. Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments. Hepatology International 2014; 8(S2): 492 doi: 10.1007/s12072-013-9515-3
|
| 2 |
Jian-Ji Li, Zhe Yang, Zan-Song Huang. Progress in basic and clinical research on molecular targeted therapy for primary hepatic carcinoma. World Chinese Journal of Digestology 2019; 27(10): 643 doi: 10.11569/wcjd.v27.i10.643
|
| 3 |
Liwei Wu, Jiao Feng, Jingjing Li, Qiang Yu, Jie Ji, Jianye Wu, Weiqi Dai, Chuanyong Guo. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomedicine & Pharmacotherapy 2021; 133: 111036 doi: 10.1016/j.biopha.2020.111036
|
| 4 |
Tetsuhiro Chiba, Eiichiro Suzuki, Tomoko Saito, Sadahisa Ogasawara, Yoshihiko Ooka, Akinobu Tawada, Atsushi Iwama, Osamu Yokosuka. Biological features and biomarkers in hepatocellular carcinoma. World Journal of Hepatology 2015; 7(16): 2020-2028 doi: 10.4254/wjh.v7.i16.2020
|
| 5 |
Lingyan Wang, Zhihui Min, Xiangdong Wang, Mushuang Hu, Dongli Song, Zhenggang Ren, Yunfeng Cheng, Yanhong Wang. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up‑regulation of TNF‑related apoptosis‑inducing ligand. Oncology Letters 2018; doi: 10.3892/ol.2018.8981
|
| 6 |
Jun Wang, Li Gong, Shao-Jun Zhu, Qiao Zhu, Li Yao, Xiu-Juan Han, Jia-Rui Zhang, Yan-Hong Li, Wei Zhang, Diego Calvisi. The Human Homolog of Drosophila Headcase Acts as a Tumor Suppressor through Its Blocking Effect on the Cell Cycle in Hepatocellular Carcinoma. PLOS ONE 2015; 10(9): e0137579 doi: 10.1371/journal.pone.0137579
|
| 7 |
Nuray Üremiş, Muhammed Mehdi Üremiş, Yılmaz Çiğremiş, Emir Tosun, Ahmet Baysar, Yusuf Türköz.
Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of
JAK
/
STAT3
,
MAPK
/
ERK
, and
AKT
/
mTOR
signaling pathways in
HepG2
cell line
. Journal of Food Biochemistry 2022; 46(10) doi: 10.1111/jfbc.14333
|
| 8 |
Xiufeng Jiang, Kang Feng, Ye Zhang, Zengyao Li, Fan Zhou, Huiqiang Dou, Tong Wang. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget 2015; 6(14): 12340 doi: 10.18632/oncotarget.3656
|
| 9 |
Bryan Fleming, Mitchell Ho. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins 2016; 8(10): 274 doi: 10.3390/toxins8100274
|
| 10 |
Bakheet Elsadek, Ahmed Mansour, Tahia Saleem, André Warnecke, Felix Kratz. The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. Digestive and Liver Disease 2017; 49(2): 213 doi: 10.1016/j.dld.2016.10.003
|
| 11 |
Ju-Yun Wu, Yu-Lueng Shih, Shih-Ping Lin, Tsai-Yuan Hsieh, Ya-Wen Lin. YC-1 Antagonizes Wnt/β-Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma. Cancers 2019; 11(5): 661 doi: 10.3390/cancers11050661
|
| 12 |
Kai-Wen Chen, Tzu-Ming Ou, Chin-Wen Hsu, Chi-Ting Horng, Ching-Chang Lee, Yuh-Yuan Tsai, Chi-Chang Tsai, Yi-Sheng Liou, Chen-Chieh Yang, Chao-Wen Hsueh, Wu-Hsien Kuo. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World Journal of Hepatology 2015; 7(10): 1412-1420 doi: 10.4254/wjh.v7.i10.1412
|
| 13 |
Haruhiko Takeda, Yukio Osaki, Yoshiaki Ohara, Azusa Sakamoto, Sumio Saito, Norihiro Nishijima, Akihiro Nasu, Hiroki Nishikawa, Hideyuki Komekado, Ryuichi Kita, Toru Kimura. A retrospective study of initial dose of sorafenib therapy in Japanese patients with unresectable hepatocellular carcinoma -experiences from a single center. Kanzo 2013; 54(3): 169 doi: 10.2957/kanzo.54.169
|
| 14 |
Chun-Han Chen, Mei-Chuan Chen, Jing-Chi Wang, An-Chi Tsai, Ching-Shih Chen, Jing-Ping Liou, Shiow-Lin Pan, Che-Ming Teng. Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
. Clinical Cancer Research 2014; 20(5): 1274 doi: 10.1158/1078-0432.CCR-12-3909
|
| 15 |
Jia-Ru Wu, Chi-Tan Hu, Ren-In You, Pei-Ling Ma, Siou-Mei Pan, Ming-Che Lee, Wen-Sheng Wu, Diego Calvisi. Preclinical Trials for Prevention of Tumor Progression of Hepatocellular Carcinoma by LZ-8 Targeting c-Met Dependent and Independent Pathways. PLOS ONE 2015; 10(1): e0114495 doi: 10.1371/journal.pone.0114495
|
| 16 |
J. Regneri, B. Klotz, M. Schartl. Genetics, Genomics and Fish Phenomics. Advances in Genetics 2016; 95: 31 doi: 10.1016/bs.adgen.2016.04.001
|
| 17 |
Zahra Farzaneh, Massoud Vosough, Tarun Agarwal, Maryam Farzaneh. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell International 2021; 21(1) doi: 10.1186/s12935-021-01924-w
|
| 18 |
Takahiro Teshima, Hirotaka Matsumoto, Hidekazu Koyama, Matias A Avila. Soluble factors from adipose tissue-derived mesenchymal stem cells promote canine hepatocellular carcinoma cell proliferation and invasion. PLOS ONE 2018; 13(1): e0191539 doi: 10.1371/journal.pone.0191539
|
| 19 |
Diego Almanza, Mehrnaz Gharaee-Kermani, Alisa Zhilin-Roth, Jose A. Rodriguez-Nieves, Cory Colaneri, Todd Riley, Jill A. Macoska. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature. Digestive Diseases and Sciences 2019; 64(5): 1257 doi: 10.1007/s10620-018-5398-4
|
| 20 |
Sang Jun Suh, Hyung Joon Yim. Current Status of Molecular Targeted Therapies in Hepatocellular Carcinoma. The Korean Journal of Gastroenterology 2013; 61(3): 136 doi: 10.4166/kjg.2013.61.3.136
|
| 21 |
Ming-Hua Hsu, Shih-Ming Hsu, Yu-Cheng Kuo, Chih-Yu Liu, Cheng-Ying Hsieh, Yuh-Ching Twu, Chung-Kwe Wang, Yuan-Hsi Wang, Yi-Jen Liao. Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. RSC Advances 2017; 7(26): 16253 doi: 10.1039/C6RA28281D
|
| 22 |
Fangmin Chen, Yifan Fang, Ruirui Zhao, Jingqing Le, Bingchen Zhang, Rui Huang, Zixuan Chen, Jingwei Shao. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. European Journal of Medicinal Chemistry 2019; 179: 916 doi: 10.1016/j.ejmech.2019.06.070
|
| 23 |
Sidharth Mehan, Saloni Rahi, Shubham Upadhayay, Andleeb Khan. Polyphenols-based Nanotherapeutics for Cancer Management. 2021; : 95 doi: 10.1007/978-981-16-4935-6_4
|
| 24 |
Guoming Deng, Yufeng Luo, Yaoming Zhang, Jinfeng Zhang, Zongyun He. Enabled homolog (ENAH) regulated by RNA binding protein splicing factor 3b subunit 4 (SF3B4) exacerbates the proliferation, invasion and migration of hepatocellular carcinoma cells via Notch signaling pathway. Bioengineered 2022; 13(2): 2194 doi: 10.1080/21655979.2021.2023983
|
| 25 |
Mohamed Bouattour, Audrey Payancé, Johanna Wassermann. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World Journal of Hepatology 2015; 7(20): 2245-2263 doi: 10.4254/wjh.v7.i20.2245
|
| 26 |
Kai-Feng Wang, Yi-Dan Chen, Li-Qin Mo, Zhen Zhang, Ya-Juan Liu, Jiang-Xiang Chen, Xin-Bing Sui, Tian Xie, Shi-Xiu Wu. Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment. World Chinese Journal of Digestology 2019; 27(7): 459 doi: 10.11569/wcjd.v27.i7.459
|
| 27 |
Wenyan Wang, Hui Wang, Yingying Ni, Zhenming Yao, Liang Ye, Jingwei Tian. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. Tumor Biology 2016; 37(7): 9221 doi: 10.1007/s13277-016-4826-3
|
| 28 |
Miral Sadaria Grandhi, Amy K. Kim, Sean M. Ronnekleiv-Kelly, Ihab R. Kamel, Mounes A. Ghasebeh, Timothy M. Pawlik. Hepatocellular carcinoma: From diagnosis to treatment. Surgical Oncology 2016; 25(2): 74 doi: 10.1016/j.suronc.2016.03.002
|
| 29 |
Andrea Ferrigno, Laura Giuseppina Di Pasqua, Mariapia Vairetti. Liver Diseases. 2020; : 587 doi: 10.1007/978-3-030-24432-3_52
|
| 30 |
Nancy S. Younis, Amal M. H. Ghanim, Sameh Saber. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-55666-x
|
| 31 |
Rachael Chang Lee, Niall Tebbutt. Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. Expert Review of Anticancer Therapy 2019; 19(4): 343 doi: 10.1080/14737140.2019.1585245
|
| 32 |
Atena Vaghf, Behzad Khansarinejad, Ehsanollah Ghaznavi-Rad, Mahdieh Mondanizadeh. The role of microRNAs in diseases and related signaling pathways. Molecular Biology Reports 2022; 49(7): 6789 doi: 10.1007/s11033-021-06725-y
|
| 33 |
Li Nan, Wan Yuan, Chen Guodong, Huang Yonghui. Multitargeting Strategy Using Tetrathiomolybdate and Lenvatinib: Maximizing Antiangiogenesis
Activity in a Preclinical Liver Cancer Model. Anti-Cancer Agents in Medicinal Chemistry 2023; 23(7): 786 doi: 10.2174/1871520622666220907115027
|
| 34 |
Ke Tang, Can Luo, Yan Li, Chenshu Lu, Wanqi Zhou, Haihong Huang, Xiaoguang Chen, Srikumar P. Chellappan. The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent. PLoS ONE 2014; 9(7): e101889 doi: 10.1371/journal.pone.0101889
|
| 35 |
Sawsan M Elsonbaty, Walid E Zahran, Fatma SM Moawed. Gamma-irradiated β-glucan modulates signaling molecular targets of hepatocellular carcinoma in rats. Tumor Biology 2017; 39(8): 101042831770870 doi: 10.1177/1010428317708703
|
| 36 |
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang. Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology 2016; 22(41): 9069-9095 doi: 10.3748/wjg.v22.i41.9069
|
| 37 |
Xia Pu, Qing-Xi Guo, Han-An Long, Cheng-Wan Yang. Effects of mTOR-STAT3 on the migra=tion and invasion abilities of hepatoma cell and mTOR-STAT3 expression in liver cancer. Asian Pacific Journal of Tropical Medicine 2014; 7(5): 368 doi: 10.1016/S1995-7645(14)60057-2
|